Lv51
1130 积分 2023-05-24 加入
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
2个月前
已完结
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
3个月前
已完结
161 Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: the randomized, double-blind, phase 3 ENGOT-Cx11/GOG-3047/KEYNOTE-A18 study
7个月前
已完结
Small cell neuroendocrine carcinoma of the cervix: Analysis of prognostic factors and patterns of metastasis
11个月前
已完结
Small cell neuroendocrine carcinoma of the cervix: Analysis of outcome, recurrence pattern and the impact of platinum-based combination chemotherapy
11个月前
已完结
ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer
11个月前
已关闭
Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix
1年前
已完结
Randomised comparison of fluorouracil plus cisplatin versus hydroxyurea in stage IIB/IVA in carcinoma of the cervix
1年前
已完结
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer
1年前
已完结
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
1年前
已完结
皖公网安备34019202002308
